Cobra Biologics is a leading international contract manufacturing organisation (CMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply.

Cobra has three GMP approved facilities in Sweden and the UK, each with expertise tailored to serving our customers around the world. We offer a broad range of integrated and stand-alone contract development and manufacturing services for clinical trials and the commercial market.

As a trusted provider and a key partner in the drug development and commercialisation process, we take pride in our manufacturing excellence and comprehensive range of services to the pharmaceutical and biotech industries.

Cobra is a Contract Manufacturing Organisation (CMO) supporting the global life sciences industry in the development and manufacture of monoclonal antibodies (mAb), recombinant proteins, DNA, viruses, phage and cell line derived products and pharmaceuticals for clinical trials and commercial supply.

Cobra Biologics was acquired by Charles River Laboratories in February 2021.